Sales of Genotyping Kits Push Visible Genetics Q2 Revenues Higher | GenomeWeb

NEW YORK, Aug 9 – Pharmacogenomics company Visible Genetics of Toronto said its second quarter revenues increased to $3.9 million, compared with $3.4 million in the year ago period, as sales of genotyping kits rose 52 percent. 

The company said its total expenses for the quarter rose to $11.3 million from $10.5 million, mostly as the result of increased expenditures stemming from the startup of its kit manufacturing facility in Atlanta as well as consolidation costs and higher sales and marketing expenses.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.